Fig. 6: HDCA promotes oleic acid synthesis in RPMs by modulating SREBP1c.

A In this cell experiment, BMDMs were treated with LPS or LPS + HDCA (20 μM) for 8 h, and the transcriptomics analysis was conducted. B Transcriptomic analysis of fatty acid metabolism pathways including oleic acid synthesis, fatty acid transportation, and fatty acid β-oxidation. C Transcriptomic profiling of enzymes and regulatory factors associated with oleic acid biosynthesis. D Relative expression of Srebf1a, Srebf1c, Scap, and Fasn in LPS-treated BMDMs with or without HDCA treatment at 8 h (n = 3 per group). E Protein expression of SREBP1 in LPS-treated BMDMs with or without HDCA treatment at 8 h. F Flow cytometry analysis of SREBP1 expression in RPMs in IFA-CTL, CFA-CTL, EAU, and HDCA-treated EAU C57BL/6J mice (n = 5 for control groups; n = 8 for treatment groups). G RAW264.7 cells were co-stimulated with LPS and HDCA (20 μM) in the presence or absence of the SREBP1 inhibitor fatostatin (25 μM), and cellular oleic acid levels were quantified at 8 h (n = 3 per group). H RAW264.7 cells were co-stimulated with LPS and HDCA, in the presence or absence of the FASN inhibitor orlistat (20 μM) for 8 h, and the cellular levels of oleic acid levels are quantified (n = 3 per group).